Cadila Healthcare | Business Upturn

Cadila Healthcare share price surges 7% as DCGI approves ZyCoV-D vaccine

Vandana Nampoothiri — Mon, 23 Aug 2021 05:12:36 +0000

Pharma company Cadila healthcare’s share price surged by 7 per cent on Monday after the firm received Emergency Use Authorization(EUA) approval from the Drug Controller General of India (DCGI) for its vaccine ZyCoV-D. The company is currently trading at Rs. 551.35.

ZyCoV-D is the world’s first Plasmid DNA Vaccine for COVID-19 and the sixth vaccine to get approval from India. The three-dose vaccine can also be administered to adolescents of the 12-18 age group. It will be administered on day zero, day 28th, and then on the 56th day.

Speaking on this development, Mr Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said “This is a historic milestone with ZyCoV-D, a product of Indian innovation becoming the world’s first DNA vaccine being offered for human use and supporting the world’s largest immunization drive. We are particularly happy that our vaccine will contribute to this fight against COVID-19 and enable the country to vaccinate a larger population especially in the age group of 12-18 years.”

On August 20, the company announced that it has signed a license and supply agreement with CHEMI SpA (“CHEMI”) of Italy, a subsidiary of Italfarmaco Group. Under the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium Injection, the generic equivalent of Sanofi Aventis’s Lovenox which Zydus will commercialize in the US.

Zydus Cadila’s ZyCoV-D vaccine to launch in September; Price to be disclosed in 1-2 weeks

Sneha Sengupta — Sat, 21 Aug 2021 14:02:30 +0000

Cadila Healthcare (Zydus Cadilla) has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first-ever Plasmid DNA Vaccine for COVID-19. The company is all set to launch the vaccine in September.

“We are making all efforts to roll it out as quickly as possible,” said Sharvil Patel, Managing Director – Zydus Cadila, speaking to the media. On pricing – Sharvil Patel, Managing Director of Zydus Cadila said the company was working with the regulatory authorities and expected clarity emerging on pricing in the next one-two weeks. “Pricing will depend on technology, delivery and volumes, and also we have a benchmark pricing,” Patel said. “The most critical challenge for us now is, how to expand production to one crore doses at our new facility,” Patel said.

Patel averred Zydus was also in discussions with potential partners to scale up vaccine production in the coming months. “The company is working with partners and we have requested from overseas for transfer of technology,” Patel said. Patel said the EUA by DCGI is based on Phase-1, Phase-2 and Phase-3 interim efficacy data. “We have not completed the full phase-3, it would take four-six months for the publication of data,” Patel said.

ZyCoV-D, is a needle-free vaccine practised by PharmaJet. It consists of a needle-free applicator, which ascertains painless intradermal vaccine delivery to the user. This is a remarkable achievement by the Plasmid DNA platform, for developing a technologically advanced vaccine suitable for human use.

Patel asserted that the platform offered rapid plug and play technology, which could be easily adapted to deal with mutations in the virus including the Delta variant.

India records 2.59 lakh fresh COVID-19 cases, 1761 deaths in last 24 hours

Nitin Anand — Tue, 20 Apr 2021 04:09:13 +0000

On Tuesday, April 20, Union Health Ministry released the data of new COVID-19 cases in India, after that India saw another day with a large surge.

Report released by the Union Health Ministry states that in the last 24 hours, India reported 2,59,170 new COVID-19 cases and 1,54,761 patients got discharge, while 1,761 people died of this deadly virus, and reached the milestone of highest single day deaths. Total active cases in India is now around 20.31 lakhs. Total death toll in India reached to 1,80,530.

https://twitter.com/ANI/status/1384355626902376454

Indian Council of Medical Research (ICMR) also released a data that shows 26,94,14,035 samples were tested up to April 19 including 15,19,486 samples tested yesterday.

The total vaccinations across the country has crossed more than 12.69 crore mark today with more than 31.03 lakh vaccine doses administered.

The country has witnessed highest number of operational COVID Vaccination Centres today till date. Total 73,600 COVID Vaccination Centres (CVCs) were operational, marking a rise of more than 28,600 operational Vaccination Centres (45,000 CVCs on an average are functional on any given day). Workplace vaccinations have also enabled such a high turnout of beneficiaries.

The cumulative number of COVID19 vaccine doses administered in the country stands at 12,69,56,032.

On April 20, in a meeting chaired by PM Narendra Modi, an important decision of allowing vaccination to everyone above the age of 18 from 1st May has been taken. PM said that the Government has been working hard from over a year to ensure that maximum numbers of Indians are able to get the vaccine in the shortest possible of time. He added that India is vaccinating people at world record pace and we will continue this with even greater momentum.

India’s National Covid-19 Vaccination Strategy has been built on a systematic and strategic end-to-end approach, proactively building capacity across R&D, Manufacturing and Administration since April 2020. While pushing for scale and speed, it has simultaneously been anchored in the stability necessary to sustainably execute the World’s Largest Vaccination Drive.

Cadila Healthcare Q3 results: Profit increased by 41%

Sanah Shah — Fri, 05 Feb 2021 11:31:03 +0000

Cadila Health, Indian multinational pharmaceutical company on Friday 5th February 2021 announced a 41% increase in its consolidated net profit to Rs 527.2 crore for the quarter ended December 2020 due to robust sales in all segments.

The company had reported a net profit of Rs 373.9 crore for the corresponding period of the fiscal last year, Cadila Healthcare said in a filing to BSE. Consolidated revenue of the company stood at Rs 3,795.6 crore for the quarter under review as against Rs 3,6381.1 for the previous year.

The filing stated, “The company’s business in India geography which comprises human health formulations business, Consumer wellness business and Animal health business posted strong growth during the quarter as it grew by 20 per cent on a year-on-year basis and registered revenues of Rs 1,643 crore.” It continued to say that US formulations business registered revenues of Rs 1,603 crore during the quarter.

The company filed 10 additional abbreviated new drug applications (ANDAs) with the United States Food and Drug Administration (USFDA) making the total number of filings to 410 and received 9 new product approvals (including 4 probable approvals) from the USFDA, according to the filing.

As the fight against COVID-19 rages on, the company was given approvals to begin phase-III clinical trials of Pegylated Interferon Alpha-2b in India and the approval to start phase III clinical trials of its vaccine ZyCoV-D, it added.

The trials for the vaccine are ongoing and will be tested across 60 locations in 30,000 healthy adult volunteers in India.

During the quarter period, the company commenced the oral anti-diabetic agent, Dapaglyn (Dapagliflozin) in India for patients suffering from Chronic Obstructive Pulmonary Disorder (COPD).

In a separate filing, Cadila Healthcare said its board has approved the reappointment of Apurva S Diwanji as an Independent Director of the company for the second term of five consecutive years, starting from May 13, 2021, to May 12, 2026.

Shares of Cadila Healthcare, the listed entity of Zydus Group, were trading at Rs 481.30 per scrip on BSE, up 0.45% from its last close.

Q4 results: Cadila Healthcare posted a net loss of Rs. 392 crore; Bajaj Electricals revenue slips by 27%

Nishi Trivedi — Fri, 19 Jun 2020 11:55:19 +0000

On Friday, the indices ended on a positive note with Nifty managed to end above 10,000 level. At close, Sensex was trading on the green mark at 34,731.7, up by 2 percent. Moreover, Bajaj Twins ended higher and gained the title of top gainers in the Nifty list.

The quarter four results of several companies were released during the session. Take a look at the results posted by some of the firms as of June 19, 2020:

1. Bajaj Electricals:
The company reported its net loss for the fourth quarter ended in March to stand at Rs 1.1 crore. This is in comparison to the net profit of Rs 24.7 crore in the same quarter last year. The revenue for the quarter under review was posted to be down by 26.7 percent at Rs 1,300.7 crore compared to Rs 1,775.2 crore.

2. Cadila Healthcare:
The Pharmaceutical company stated a 14.82 percent decline in its consolidated net profit at Rs 391.9 crore for the fourth quarter in FY20. This was owing to the one-time loss faced at Rs 52.5 crore. Earlier, the company reported its net profit for the same quarter last year to stand at Rs. 460.1 crore.
Further, the firm’s consolidated revenue for the quarter was posted at Rs 3,752.1 crore. Last year, the revenue was reported at Rs. 3,732.8 crore, marginally lower than current fiscal.

3. The Ramco Cements:
The Chennai based company posted a 11.6 percent drop in its net profit at Rs. 146.2 crore for the fourth quarter in the current fiscal year. Earlier, the net profit in the quarter in the corresponding year was stated at Rs 165.4 crore. The revenue faced a 9.3 percent decline to stand at Rs 1,390 crore compared to Rs 1,532.4 crore, previous year.

4. Unichem Laboratories:
The Pharmaceutical company reported its net loss for the quarter four ended in March to stand at Rs. 17.2 crore. Moreover, the company reported a profit of Rs 38 crore in the last fiscal, same quarter. As for the revenue, for the quarter under review the company met with 14.6 percent drop at Rs 320.2 crore compared to Rs 374.9 crore last fiscal.